The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease

• Main Authors: Zhijia Zhou, Penghua Lai, Shaoliang Zhang, Yujie Wang, Ning Qu, Dawei Lu, Liangqin Gao, Lingxia Xu, Yanmiao Yang, Ting Zhang, Xue Sun, Xiaoting Zheng, Yaoyu Liu, Huiqing Liang, Shaodong Chen
• Format: Article
• Language: English
• Published: Hindawi Limited 2021-01-01
• Series: BioMed Research International
• Online Access: http://dx.doi.org/10.1155/2021/6612477

Myeloid-derived suppressor cells (MDSCs) have attracted attention due to their important role in inflammation. Several studies have investigated the involvement of MDSCs in chronic liver disease. However, due to the difference of MDSC phenotypes, patient types, and sample sources among the studies, the results are inconsistent and controversial. We took advantage of a large well-defined cohort of 98 (24 patients with CHB, 18 with NAFLD, 13 with HCC, 16 with PBC, and 27 with AIH) patients with liver inflammation and 12 healthy controls to investigate the expression of MDSCs, and the relationships between the expression of hepatic MDSCs and the clinical characteristics were analyzed. We found that the expression of CD11b+CD33+ MDSCs is closely related to chronic liver disease and positively correlated with clinical parameters such as ALT, AST, and globulin. Ultimately, the present study suggests that hepatic CD11b+CD33+ MDSCs are increased in HCC and AIH and positively correlate with the liver stages of hepatitis activity and liver fibrosis stage.